BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE

Overview

cited authors

Perkovic, Vlado; Baeres, Florian; Bakris, George; Bosch-Traberg, Heidrun; Idorn, Thomas; Mahaffey, Kenneth; Mann, Johannes; Mersebach, Henriette; Rossing, Peter; Tuttle, Katherine; Pratley, Richard

authors

Pratley, Richard Edwin, MD

Publication Date

May 1, 2022

webpage

Web of Science

published in

NEPHROLOGY DIALYSIS TRANSPLANTATION Journal

Additional Document Info

start page

I893

end page

I894

volume

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.